Clone designation: 143-13 · Host: mouse · Application(s): FC and IF · Interleukin-2 (IL-2) elicits its effects by binding to a multi-subunit cell-surface receptor that is inducible by various mitogens.^1,2,3 The highest affinity for IL-2 is achieved when all 3 subunits (IL-2Rα or CD25, IL-2Rβ or CD122, and IL-2Rγ or CD132) are expressed together forming a heterotrimeric complex⁴. CD25 is inducible in T-cells by antigen, mitogen or antibodies bound to the T-cell receptor CD3.^2,5 Binding of IL-2 to IL-2R on NK cells results in their conversion to LAK cells, which release several other cytokines (TNF, INF-γ, and GM-CSF).^4,6 Activated T-cells will respond to IL-2 by proliferating and secreting cytokines and cytolytic molecules. Activated B cells will proliferate and secrete antibodies.⁷

1 Ruscetti, F.W., and Gallo, R.C. Human T-lymphocyte growth factor: Regulation of growth and function of T lymphocytes. Blood 57(3) 379-394 (1981).

2 Robb, R.J., Munck, A., and Smith, K.A. T cell growth factor receptors. Quantification, specificity, and biological relevance. J Exp Med 154 1455-1474 (1981).

3 Leonard, W.J., Krönke, M., Peffer, N.J., et al. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci USA 82 6281-6285 (1985).

4 Waldmann, T.A. The IL-2/IL-2 receptor system: A target for rational immune intervention. Immunol Today 14 264-269 (1993).

5 Venuta, S., Mertelsmann, R., Welte, K., et al. Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies. Blood 61(4) 781-789 (1983).

6 Smith, K.A. The interleukin 2 receptor. Annu Rev Cell Biol 5 397-425 (1989).

7 Kaplan, G., Cohn, Z.A., and Smith, K.A. Rational immunotherapy with interleukin 2. Biotechnology 10 157-162 (1992).

Litherland, S.A., Xie, X.T., Hutson, A.D., et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 104 515-523 (1999).

Biancotto, A., Grivel, J., Gondois-Rey, F., et al. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78(19) 10507-10515 (2004).

Waldmann, T.A. The IL-2/IL-2 receptor system: A target for rational immune intervention. Immunol Today 14 264-269 (1993).

Ruscetti, F.W., and Gallo, R.C. Human T-lymphocyte growth factor: Regulation of growth and function of T lymphocytes. Blood 57(3) 379-394 (1981).

Kaplan, G., Cohn, Z.A., and Smith, K.A. Rational immunotherapy with interleukin 2. Biotechnology 10 157-162 (1992).

Robb, R.J., Munck, A., and Smith, K.A. T cell growth factor receptors. Quantification, specificity, and biological relevance. J Exp Med 154 1455-1474 (1981).

Leonard, W.J., Krönke, M., Peffer, N.J., et al. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci USA 82 6281-6285 (1985).

Venuta, S., Mertelsmann, R., Welte, K., et al. Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies. Blood 61(4) 781-789 (1983).

Franzese, O., Bonmassar, E., Marcucci, A., et al. Functional antagonism between IL-2 and PGA₁ or PGJ₂ in the control of proliferation of human cord blood-derived mononuclear cells. Int J Immunopharmacol 18 609-622 (1996).

Smith, K.A. The interleukin 2 receptor. Annu Rev Cell Biol 5 397-425 (1989).

Show all 10 Hide all but first 3